HOME >> BIOLOGY >> NEWS
Improved NIST SRM aids lead poisoning detection

od obtained from goats. The red blood cell system of an adult goat is much closer to that of a human, making it a better model for assessing proficiency for erythrocyte protoporphyrin, a biomarker of lead exposure. NISTs partner in developing 955c, the New York State Department of Healths Wadsworth Center Lead Poisoning Laboratory, dosed adult goats with lead acetate to produce blood pools containing lead physiologically bound to red blood cells.* The new SRM provides a better match than its predecessor to the blood samples clinicians analyze. The lead concentrations were determined by NIST using highly specialized methodology that resulted in high accuracy and low measurement uncertainty.

The changing goal line for blood lead concentration makes SRM 955c especially useful to laboratories. The lowest lead concentration level in the previous standard was 4 micrograms per deciliter or 40 parts per billion. In contrast, the lowest lead concentration level of SRM 955c is 0.4 microgram per deciliter or four parts per billion, the level of lead in an undosed animal. It is intended to represent the natural level of lead in an unexposed human population (although it is not yet known if any lead is naturally present in human blood). The lowest concentration in the SRM is 25 times lower than the DHHS 2010 goal, and will enable the development of next generation clinical methods that will be needed to accurately measure blood lead levels in children as progress is made toward eliminating lead exposure.

In addition to lead, levels two through four of SRM 955c contain added amounts of arsenic, cadmium, mercury, methylmercury and ethylmercury to facilitate future efforts to develop clinical methods to measure these toxins in human blood. At present, NIST provides information values only for the concentrations of cadmium and total mercury (including methylmercury and ethylmercury.) As values become available for arsenic, methylmercury and ethylmercury, the cert
'"/>

Contact: John Blair
john.blair@nist.gov
301-975-4261
National Institute of Standards and Technology (NIST)
3-Aug-2007


Page: 1 2 3

Related biology news :

1. Improved predictions of warming-induced extinctions sought
2. Improved imaging for identifying breast cancer in overweight women
3. Improved speech without vocal cords
4. Improved blood safety measures from Pall can increase platelet availability
5. Improved statistical tools reveal many linked loci
6. Improved process of drying lumber may save millions
7. Improved cancer treatments aim of new biology research program
8. Improved recipe for magnetic brain stimulation
9. Improved molecular switch could serve as sensor, medical tool
10. Leading the fight against food poisoning
11. Dipstick test could reduce risk of food poisoning by rapidly detecting spoilage

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Improved NIST SRM aids lead poisoning detection

(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: